U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H27N3O7S
Molecular Weight 501.552
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PG-530742

SMILES

COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C(O)=O

InChI

InChIKey=JAYVKNDQKXUNOJ-UHFFFAOYSA-N
InChI=1S/C24H27N3O7S/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30)

HIDE SMILES / InChI

Molecular Formula C24H27N3O7S
Molecular Weight 501.552
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

PG-116800 is a member of the hydroxyproline-based hydroxamic acid class of matrix metalloproteinase (MMP) inhibitors. PG-116800 did not modify matrix structure in osteoarthritic patients. Also, it had unexpected side effects on muscle and skeleton; it limited joint mobility, and caused arthralgia, hand oedema, palmar fibrosis, Dupuytren’s contracture and persistent tendon thickness or nodules. PG-116800 failed to reduce left ventricular remodeling or improve clinical outcomes after myocardial infarction.

Approval Year

PubMed

PubMed

TitleDatePubMed
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.
2006 Feb 15
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
2006 Jul 4
The quest for the Holy Grail: a disease-modifying osteoarthritis drug.
2007
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.
2007

Sample Use Guides

25 mg, 50 mg, 100 mg, or 200 mg taken twice daily for 12 months
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:31:10 GMT 2023
Edited
by admin
on Sat Dec 16 02:31:10 GMT 2023
Record UNII
F94T42GL80
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PG-530742
Common Name English
PG-116800
Code English
PGE7113313
Code English
PGE-7113313
Code English
4-HEXYNOIC ACID, 2-(((4-((4-METHOXYBENZOYL)AMINO)PHENYL)SULFONYL)AMINO)-6-(4-MORPHOLINYL)-
Common Name English
Code System Code Type Description
MESH
C512048
Created by admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
PRIMARY
FDA UNII
F94T42GL80
Created by admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
PRIMARY
DRUG BANK
DB05495
Created by admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
PRIMARY
PUBCHEM
9848869
Created by admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
PRIMARY
CAS
291533-11-4
Created by admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID10951756
Created by admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
PRIMARY